Navigation Links
Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
Date:11/24/2009

BEIJING, Nov. 24 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic China, today reported it will exhibit at the 62nd PHARMCHINA as a member of the Beijing pharmaceutical delegation.

Time: November 26-28, 2009

Venue: International Convention Center, Chengdu

The Beijing delegation features more than twenty pharmaceutical companies from Beijing, including Beijing Shuanghe Group, Beijing Pharmaceutical Group, and Tongrentang. As a member of the delegates, Lotus will continue to market its drugs that have established certain market share in China and introduce three potential new drugs that are subject to the State Food and Drug Administration's approval. These drugs include Laveo-Bambutero for asthma, Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.

About PHARMCHINA

PHARMCHINA is the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.

    For more information, please contact:

    Lotus Pharmaceuticals, Inc.
     Yan ZENG, CFO
     Tel:   +86-10-6389-9868
     Email: zy@lotuspharma.com

SOURCE Lotus Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
5. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
10. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
11. BioMarin Acquires Huxley Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... titled, "Breast Imaging Technologies Market by Type: Global Opportunity Analysis ... technologies market size was valued at $2,544 million in 2015 ... at a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in 2015. ...
(Date:1/18/2017)... Iowa , Jan. 18, 2017   ... that subsidiary Caretta Therapeutics plans, in the second ... Venodol, a topical roll-on intended to provide relief ... opioid and steroidal analgesics. It was developed under ... to commercialize products derived from snake venom. ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  Dermata ... innovative products to treat a variety of dermatological ... lead compound DMT210, in a Phase 2 acne ... developed to downregulate the proinflammatory cytokines in the ... in acne rosacea. This clinical ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor plans to run the ... charity that provides free surgery to poor children suffering from cleft lip and cleft ... have run to support the efforts of the American Heart Association and the Leukemia ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Dr. Farhan Qureshi ... cosmetic and implants dentistry. His modern dental practice has two convenient office locations in ... 2017 Top Rated Dentist for the Alexandria area. This award confirms the ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... ranging from gum disease to enamel erosion, and those dental problems can increase ... of Public Health, many pregnant women are failing to get the dental care ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... point of difference. Eden Activewear is a stand-out company for several differences from ... online and only manufacture on demand, this is called 'Agile' manufacturing - ...
(Date:1/17/2017)... ... 17, 2017 , ... Kevin Harrington (one of the original Sharks from mega-hit ... regarding the topic of Beauty and Personal Care. , Everyone makes ... way to commit to these changes than beginning with personal care and beauty products? ...
Breaking Medicine News(10 mins):